[1] Lok CE, Huber TS, Lee T, et al., 2020, KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis, 75(4 Suppl 2): S1-S164. [2] Vascular Access Working Group of the Blood Purification Center Branch of the Chinese Hospital Association, 2019, Expert Consensus on Vascular Access for Hemodialysis in China (2nd Edition). Chinese Journal of Blood Purification, 18(6): 365-381. [3] Roy-Chaudhury P, Sukhatme VP, Cheung AK, 2006, Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. Journal of the American Society of Nephrology, 17(4): 1112-1127. [4] Ma S, Duan S, Liu Y, et al., 2022, Intimal Hyperplasia of Arteriovenous Fistula. Annals of Vascular Surgery, 85: 444-453. [5] Li L, Terry CM, Shiu YT, et al., 2008, Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney International, 74(10): 1247-1261. [6] Trerotola SO, Kwak A, Clark TW, et al., 2005, Prospective study of balloon-injured veins with metal stent placement after unsuccessful angioplasty. J Vasc Interv Radiol, 16(9): 1225-1231. [7] Lookstein R, Haruguchi H, Suemitsu K, et al., 2023, IN.PACT AV Access randomized trial of drug-coated balloons for dysfunctional arteriovenous fistulae: Clinical outcomes through 36 months. J Vasc Interv Radiol, 34(12): 2093-2102. [8] Dong JH, Ge YC, 2019, Mechanism of autogenous arteriovenous fistula dysfunction. Chinese Journal of Nephrology, Dialysis & Transplantation, 28(4): 379-384. [9] Wang LH, Jiang AL, Wei F, 2015, Hemodynamic changes after the establishment of arteriovenous fistula. Chinese Journal of Nephrology, 31(10): 797-800. [10] Hu PP, Yang T, Wang YZ, 2011, Research progress on the mechanism of vascular intimal hyperplasia in arteriovenous fistula. Chinese Journal of Blood Purification, 10(10): 564-566. [11] Ren ZT, Zhou T, He LQ, et al., 2023, Research on the molecular biological mechanism of arteriovenous fistula dysfunction. Journal of Clinical Nephrology, 23(12): 1041-1044. [12] Liu Q, Ba YG, 2022, Research progress on the pathological mechanism of autogenous arteriovenous fistula dysfunction. Progress in Clinical Medicine, 12(6): 5968-5973. [13] Zheng JP, 2024, Effects of notoginsenoside R1 on vascular endothelial injury and intimal hyperplasia in a rat model of arteriovenous fistula. Fujian Medical Journal, 46(7): 76-79. [14] Fang X, Sui XL, Huang WT, et al., 2024, Regulatory mechanism of the HIF-1α/HO-1/VEGF-A signaling pathway in poor maturation of autogenous arteriovenous fistula. Journal of Practical Clinical Medicine, 28(18): 101-105, 148. [15] Chen RR, Yu Y, Fan YP, 2016, Cellular and molecular pathological mechanisms of vascular intimal hyperplasia in arteriovenous fistula. Chinese Journal of Nephrology, Dialysis & Transplantation, 25(5): 475-478, 450. [16] Steucke KE, Tracy PV, Hald ES, et al., 2015, Vascular smooth muscle cell functional contractility depends on extracellular mechanical properties. J Biomech, 48(12): 3044-3051. [17] Martin-Garrido A, Williams HC, Lee M, et al., 2013, Transforming growth factor β inhibits platelet derived growth factor-induced vascular smooth muscle cell proliferation via Akt-independent, Smad-mediated cyclin D1 downregulation. PLoS One, 8(11): e79657. [18] Li P, Zhang Z, Zhang F, et al., 2021, Retracted: Effects of 3-Tetrazolyl Methyl-3-Hydroxy-Oxindole Hybrid (THOH) on Cell Proliferation, Apoptosis, and G2/M Cell Cycle Arrest Occurs by Targeting Platelet-Derived Growth Factor D (PDGF-D) and the MEK/ERK Signaling Pathway in Human Lung Cell Lines SK-LU-1, A549, and A-427. Med Sci Monit, 27: e932328. [19] Khan R, Kadamkode V, Kesharwani D, et al., 2020, Circulatory miR-98-5p levels are deregulated during diabetes and it inhibits proliferation and promotes apoptosis by targeting PPP1R15B in keratinocytes. RNA Biol, 17(2): 188-201. [20] Zhou J, Yang J, Dong Y, et al., 2022, Oncostatin M receptor regulates osteoblast differentiation via extracellular signal-regulated kinase/autophagy signaling. Stem Cell Res Ther, 13(1): 278. [21] Han YC, Liu YT, Zhang H, et al., 2023, VDR alleviates endothelial cell injury in arteriovenous fistula through inhibition of P66Shc-mediated mitochondrial ROS. Sci Rep, 13(1): 11088. [22] Sadaghianloo N, Contenti J, Declemy S, et al., 2021, Hypoxia and hypoxia-inducible factors promote the development of neointimal hyperplasia in arteriovenous fistula. J Physiol, 599(8): 2299-2321. [23] Liu X, Zhu Y, Zheng W, et al., 2019, Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Artif Cells Nanomed Biotechnol, 47(1): 1628-1634. [24] Yang Y, Zhou H, Liu W, et al., 2018, Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. Oncol Lett, 16(5): 6515-6521. [25] Jeong JW, Kim JW, Ku SK, et al., 2015, Essential oils purified from Schisandrae semen inhibits tumor necrosis factor-α-induced matrix metalloproteinase-9 activation and migration of human aortic smooth muscle cells. BMC Complement Altern Med, 15: 7. [26] Xu SZ, Xie MJ, 2022, Application effect of short-term clopidogrel administration after arteriovenous fistula surgery in preventing fistula stenosis. Jiangxi Medical Journal, 57(8): 866-869. [27] Cao ZJ, Fu P, Zhou L, 2020, Preventive pharmacological interventions for hemodialysis vascular access dysfunction based on guidelines. West China Medical Journal, 35(7): 775-780. [28] Liu YD, Hu LZ, 2017, Prevention and treatment of stenosis and thrombosis in artificial vascular arteriovenous fistula. Journal of Clinical Nephrology, 17(4): 196-199. [29] Swain SK, Arora RK, Sharma SK, et al., 2022, Vertebral arteriovenous fistula in neurofibromatosis type 1. J Neurosurg Sci, 66(1): 54-61. [30] Nilsson J, 2017, Atherosclerotic plaque vulnerability in the statin era. Eur Heart J, 38(21): 1638-1644. [31] Lin QJ, Lu CL, Song CL, et al., 2023, Hemodynamic analysis based on specific patients with autogenous arteriovenous fistula. Modeling and Simulation, 12(2): 892-900. [32] Yang HY, Liu YW, Aman GA, et al., 2022, Hemodynamic analysis of functional end-to-side anastomosis in autogenous arteriovenous fistula. Medical Biomechanics, 37(1): 118-123. [33] ElKassaby M, Elsayed N, Mosaad A, et al., 2021, End-to-side versus side-to-side anastomosis with distal vein ligation for arteriovenous fistula creation. Vascular, 29(5): 790-796. [34] Gong QP, Zhang YY, Li XP, et al., 2012, Perioperative nursing interventions for arteriovenous fistula formation in hemodialysis. Minimally Invasive Medicine, 7(2): 134-136. [35] de Castro-Santos G, Shiomatsu GY, Oliveira RMDS, et al., 2021, Intraoperative vascular Doppler ultrasound blood flow and peak systolic velocity predict early patency in hemodialysis arteriovenous fistula. J Vasc Bras, 20: e20210098. [36] Lu MZ, Li ZK, Lei ZH, et al., 2022, Effect of endovascular angioplasty on the treatment of autogenous arteriovenous fistula stenosis and influencing factors of postoperative restenosis and dysfunction. Chinese Journal of Physicians, 24(9): 1359-1362. [37] Zheng Q, Xie B, Xie X, et al., 2021, Predictors associated with early and late restenosis of arteriovenous fistulas and grafts after percutaneous transluminal angiography. Ann Transl Med, 9(2): 132. [38] Kim WS, Pyun WB, Kang BC, 2011, The primary patency of percutaneous transluminal angioplasty in hemodialysis patients with vascular access failure. Korean Circ J, 41(9): 512-517. [39] Tang S, Lo CY, Tso WK, et al., 1998, Percutaneous transluminal angioplasty for stenosis of arteriovenous fistulae: a review of local experience. Hong Kong Med J, 4(1): 36-41. [40] Taghavi M, Lengelé A, Laureys M, et al., 2025, Antiphospholipid antibodies positivity as a potential risk factor for restenosis following arteriovenous fistula stenting in hemodialysis patients: a pilot study. Front Med (Lausanne), 11: 1497810. [41] Chen Z, Matsumura M, Mintz GS, et al., 2022, Prevalence and Impact of Neoatherosclerosis on Clinical Outcomes Following Percutaneous Treatment of Second-Generation Drug-Eluting Stent Restenosis. Circ Cardiovasc Interv, 15(9): e011693. [42] Zheng X, Xi W, Shen X, et al., 2025, Ultrasound-guided Nitinol Stent Implantation for the Treatment of Early Restenosis of Arteriovenous Fistula: A Study of 69 Cases with 1-Year Outcomes. J Vasc Access, 26(4): 1399-1407. [43] Kim KH, Kim DI, Kim IH, et al., 2009, Therapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation. Korean Circ J, 39(10): 408-413. [44] Bashar K, Conlon PJ, Kheirelseid EA, et al., 2016, Arteriovenous Fistula in Dialysis Patients: Factors Implicated in Early and Late AVF Maturation Failure. Surgeon, 14(5): 294-300. [45] Zhang N, Tian Y, Cai HX, et al., 2022, Application Research of Covered Stents in the Treatment of Autologous Arteriovenous Fistula Stenosis. Chinese Journal of Integrative Traditional and Western Medicine in Surgery, 28(4): 464-467. [46] Yu H, Chi Y, Wang B, 2023, The Efficacy of Percutaneous Transluminal Angioplasty and Arteriovenous Fistula Reconstruction for Immature Arteriovenous Fistula. BMC Nephrol, 24(1): 304. [47] Cai C, Zhao C, Kilari S, et al., 2020, Experimental Murine Arteriovenous Fistula Model to Study Restenosis After Transluminal Angioplasty. Lab Anim (NY), 49(11): 320-334. [48] Khanna A, Oropeza BP, Huang NF, 2022, Engineering Spatiotemporal Control in Vascularized Tissues. Bioengineering (Basel), 9(10): 22-32. [49] Hou F, Zhao B, Zhang LH, et al., 2025, Efficacy of Peripheral Cutting Balloon in the Treatment of Anastomotic Stenosis of Autologous Arteriovenous Fistula. Chinese Journal of Nephrology, Dialysis & Transplantation, 34(4): 329-334. [50] Aftab SA, Tay KH, Irani FG, et al., 2014, Randomized Clinical Trial of Cutting Balloon Angioplasty Versus High-Pressure Balloon Angioplasty in Hemodialysis Arteriovenous Fistula Stenoses Resistant to Conventional Balloon Angioplasty. J Vasc Interv Radiol, 25(2): 190-198. [51] Huo G, Xue J, Zheng J, et al., 2025, Factors Associated with Patency Following Drug-Coated Balloon Angioplasty of Hemodialysis Access. Sci Rep, 15: 19375. [52] Lookstein RA, Haruguchi H, Ouriel K, et al., 2020, Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas. N Engl J Med, 383(8): 733-742. [53] Zhang L, Zhang F, Li X, et al., 2025, Real-World Effectiveness of DKutting Scoring Balloon for AVF and AVG Stenosis and Thrombosis. Ren Fail, 47(1): 2553807. [54] Zhuang KD, Wei MWQ, Min SXCJ, et al., 2024, Combining Cutting and Drug-Eluting Balloon for Resistant Arteriovenous Fistula Stenosis (CONCERTO) - A Pilot Study. Interv Radiol (Higashimatsuyama), 10: e20240030. [55] Zhang R, Li W, Yang J, et al., 2025, The Role of Luteolin in Inhibiting Prostaglandin-Endoperoxide Synthase 2 to Relieve Neointimal Hyperplasia in Arteriovenous Fistula. Adv Biol (Weinh), 9(4): e2400437. [56] Roy-Chaudhury P, Arend L, Zhang J, et al., 2007, Neointimal Hyperplasia in Early Arteriovenous Fistula Failure. Am J Kidney Dis, 50(5): 782-790. [57] Zheng J, Yan Y, Chen QK, et al., 2015, Experimental Study on Chitosan Inhibiting Intimal Hyperplasia in Rabbit Arteriovenous Fistula. Chinese Journal of Nephrology, 31(5): 367-371. [58] Kashba SR, Patel NJ, Grace M, et al., 2015, Angiographic, Hemodynamic, and Histological Changes in an Animal Model of Brain Arteriovenous Malformations Treated with Gamma Knife Radiosurgery. J Neurosurg, 123(4): 954-960. [59] Qiao Z, Wang F, Han D, et al., 2024, Ultrasound-Guided Periadventitial Administration of Rapamycin-Fibrin Glue Attenuates Neointimal Hyperplasia in the Rat Carotid Artery Injury Model. Eur J Pharm Sci, 192: 106610. [60] Kim S, Kim Y, Hwang JW, et al., 2017, Inhibitory Effect of Sustained Perivascular Delivery of Paclitaxel on Neointimal Hyperplasia in the Jugular Vein After Open Cutdown Central Venous Catheter Placement in Rats. Ann Surg Treat Res, 92(2): 97-104. [61] Hu K, Guo Y, Li Y, et al., 2022, Oxidative Stress: An Essential Factor in the Process of Arteriovenous Fistula Failure. Front Cardiovasc Med, 9: 984472. [62] Kim S, Kim Y, Hwang JW, et al., 2017, Inhibitory Effect of Sustained Perivascular Delivery of Paclitaxel on Neointimal Hyperplasia in the Jugular Vein After Open Cutdown Central Venous Catheter Placement in Rats. Ann Surg Treat Res, 92(2): 97-104. [63] Raghu H, Lepus CM, Wang Q, et al., 2017, CCL2/CCR2, but Not CCL5/CCR5, Mediates Monocyte Recruitment, Inflammation, and Cartilage Destruction in Osteoarthritis. Ann Rheum Dis, 76(5): 914-922. [64] Habibie YA, Emril DR, Azharuddin A, et al., 2023, Effect of Umbilical Cord Mesenchymal Stem Cells on Hypoxia-Inducible Factor-1 Alpha (HIF-1α) Production in an Arteriovenous Fistula (AVF) Animal Model: A Preliminary Study. Narra J, 3(3): e225. [65] Wu W, Song A, Xie K, et al., 2024, Characteristics of T Cell Premature Senescence in Maintenance Hemodialysis Patients. Inflamm Res, 73(8): 1299-1309. [66] Gao M, Wang J, 2022, Risk Factors of Arteriovenous Fistula Stenosis in Patients with Maintenance Hemodialysis. Evid Based Complement Alternat Med, 2022: 2968122. [67] Rai V, Radwan MM, Nooti S, et al., 2022, TLR-4 Inhibition Attenuates Inflammation, Thrombosis, and Stenosis in Arteriovenous Fistula in Yucatan Miniswine. Cardiol Cardiovasc Med, 6(5): 432-450. [68] Roy-Chaudhury P, Khan R, Campos B, et al., 2014, Pathogenetic Role for Early Focal Macrophage Infiltration in a Pig Model of Arteriovenous Fistula (AVF) Stenosis. J Vasc Access, 15(1): 25-28. [69] Deng HY, Zhu HL, Research Progress on the Mechanism of Nrf2 Activators in Resisting Skin Oxidative Damage. In The 8th National Conference on Photobiology. [70] Sandouka S, Shekh-Ahmad T, 2021, Induction of the Nrf2 Pathway by Sulforaphane Is Neuroprotective in a Rat Temporal Lobe Epilepsy Model. Antioxidants (Basel), 10(11): 1702. [71] Accardi G, Scola L, Aiello A, et al., 2018, The Signature of Longevity in Sicily. J Biol Regul Homeost Agents, 32(4 Suppl 1): 9-13. [72] Smith RA, Murphy MP, 2010, Animal and Human Studies with the Mitochondria-Targeted Antioxidant MitoQ. Ann N Y Acad Sci, 1201: 96-103. [73] Greco T, Shafer J, Fiskum G, 2011, Sulforaphane Inhibits Mitochondrial Permeability Transition and Oxidative Stress. Free Radic Biol Med, 51(12): 2164-2171. [74] Xia F, Rai V, Agrawal DK, 2024, Vascular and Perivascular Role in the Regulation of Angiogenesis: Impact on Arteriovenous Fistula Maturation. Arch Intern Med Res, 7(4): 284-296. [75] Lv D, Chu L, Du Y, et al., 2025, Sulforaphane Alleviates Membranous Nephropathy by Inhibiting Oxidative Stress-Associated Podocyte Pyroptosis. Iran J Basic Med Sci, 28(2): 237-244. [76] Voorzaat BM, van Schaik J, van der Bogt KE, et al., 2017, Improvement of Radiocephalic Fistula Maturation: Rationale and Design of the Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT) Study - A Randomized Controlled Trial. J Vasc Access, 18(Suppl 1): 114-117. [77] Xia F, Rai V, Agrawal DK, 2024, Vascular and Perivascular Role in the Regulation of Angiogenesis: Impact on Arteriovenous Fistula Maturation. Arch Intern Med Res, 7(4): 284-296. [78] Bennett MR, Anglin S, McEwan JR, et al., 1994, Inhibition of Vascular Smooth Muscle Cell Proliferation In Vitro and In Vivo by c-myc Antisense Oligodeoxynucleotides. J Clin Invest, 93(2): 820-828. [79] Wang J, Liu K, Shen L, et al., 2011, Small Interfering RNA to c-myc Inhibits Vein Graft Restenosis in a Rat Vein Graft Model. J Surg Res, 169(1): e85-91. [80] Ibrahim Fouad G, 2023, Sulforaphane, an Nrf-2 Agonist, Modulates Oxidative Stress and Inflammation in a Rat Model of Cuprizone-Induced Cardiotoxicity and Hepatotoxicity. Cardiovasc Toxicol, 23(1): 46-60. [81] Li D, Yan D, Liu W, et al., 2011, Foxc2 Overexpression Enhances Benefit of Endothelial Progenitor Cells for Inhibiting Neointimal Formation by Promoting CXCR4-Dependent Homing. J Vasc Surg, 53(6): 1668-1678. [82] Hristov M, Zernecke A, Liehn EA, et al., 2007, Regulation of Endothelial Progenitor Cell Homing After Arterial Injury. Thrombosis and Haemostasis, 98(2): 274-277. [83] Asahara T, Murohara T, Sullivan A, et al., 1997, Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science, 275(5302): 964-967. [84] Urbich C, Dimmeler S, 2004, Endothelial Progenitor Cells: Characterization and Role in Vascular Biology. Circ Res, 95(4): 343-353. [85] Wang D, Wang X, Zhang Z, et al., 2019, Programmed Release of Multimodal, Cross-Linked Vascular Endothelial Growth Factor and Heparin Layers on Electrospun Polycaprolactone Vascular Grafts. ACS Appl Mater Interfaces, 11(35): 32533-32542. [86] Singh S, Wu BM, Dunn JC, 2012, Delivery of VEGF Using Collagen-Coated Polycaprolactone Scaffolds Stimulates Angiogenesis. J Biomed Mater Res A, 100(3): 720-727. [87] Besseling PJ, Szymczyk W, Teraa M, et al., 2024, Off-the-Shelf Synthetic Biodegradable Grafts Transform In Situ into a Living Arteriovenous Fistula in a Large Animal Model. Adv Healthc Mater, 13(17): e2303888. [88] Pigeot S, Klein T, Gullotta F, et al., 2021, Manufacturing of Human Tissues as Off-the-Shelf Grafts Programmed to Induce Regeneration. Adv Mater, 33(43): e2103737. [89] Davidson BL, Stein CS, Heth JA, et al., 2000, Recombinant Adeno-Associated Virus Type 2, 4, and 5 Vectors: Transduction of Variant Cell Types and Regions in the Mammalian Central Nervous System. Proc Natl Acad Sci U S A, 97(7): 3428-3432. [90] Barcena AJR, Perez JVD, Bernardino MR, et al., 2023, Bioresorbable Mesenchymal Stem Cell-Loaded Electrospun Polymeric Scaffold Inhibits Neointimal Hyperplasia Following Arteriovenous Fistula Formation in a Rat Model of Chronic Kidney Disease. Adv Healthc Mater, 12(26): e2300960.